Added to YB: 2026-04-02
Pitch date: 2026-03-31
290650.KQ [bullish]
L&C BIO Co.,LTD
-8.09%
current return
Author Info
The Consumer Ascent shares fundamental research and channel checks on emerging global consumer brands. Sign up for the newsletter.
Company Info
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products.
Market Cap
KRW 1.7T
Pitch Price
KRW 70.5K
Price Target
96.0K (+48%)
Dividend
N/A
EV/EBITDA
152.45
P/E
-11.56
EV/Sales
20.33
Sector
Biotechnology
Category
growth
Re2O: The Next Generation Botox - L&C Bio
290650.KQ: L&C Bio's Re2O injectable (processed human ECM) commands 80-170% price premium over incumbent Rejuran ($650K vs $242K-$363K/session) w/ faster adoption (500→2,000+ clinics in <1yr). Production scaling from 30K to 80K units/month starting May '26 (vs H2 guidance), targeting 150K+ by Oct. Korea dominance, Japan live, China trials 2026. Legacy surgical grafts ($100M rev, stable margins) fund expansion. Capacity-constrained 2025 rev $85.5M understates demand; 2027E rev ~$300M w/ Re2O at $200M implies EPS ~$3,000-$3,500. At 30x fwd, PT ~₩96K. Bull case: global platform w/ manufacturing moat. Risks: ramp delays, China NMPA timeline, U.S. FDA path unclear. May production inflection critical catalyst.
Read full article (21 min)